Live Evaluations

Atopic Dermatitis: WCM23 Satellite Symposium


CME Satelllite Symposium - February 19, 2023 11:50 AM EST

Strategies to Alleviate the Multidimensional Burden of Moderate-to-Severe Atopic Dermatitis in Children and Adolescents

This activity is supported by an educational grant from Sanofi Regeneron Pharmaceuticals. 

Learning Objectives

At the completion of this activity, participants should be better able to:

  • Underline the multidimensional burden of moderate-to-severe atopic dermatitis in children and adolescents

  • Recall the multidimensional benefits of systemic biologics for the management of moderate-to-severe atopic dermatitis in children and adolescents

  • Discuss seamless integration of biologics into daily clinical practice through enhanced multidisciplinary care

Intended Audience
This activity has been designed for dermatologists, dermatology physician assistants, dermatology nurse practitioners, and other providers involved in the care of patients.
Alexandra Golant, MD

Medical Director, Dermatology Faculty Practice
Associate Director, Residency Program
Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, NY

Benjamin Lockshin, MD

EVP of Strategic Initiatives
Director of the Clinical Trials Center
Assistant Professor
US Dermatology Partners
Georgetown University
Rockville, MD

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Nevada and CMEsquared. The University of Nevada is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The University of Nevada designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures & Disclaimers


In accordance with the ACCME Standards for Commercial Support, balance, independence, objectivity, and scientific rigor are ensured in all CME activities. This requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with any ineligible companies. In addition, the content of this material has been approved by an independent peer reviewer. 

Disclosures are as follows:

Alexandra Golant, MD

Consultant: Regeneron, Sanofi, Lilly, Incyte, Dermavant, Arcutis, LEO Pharma, Janssen 

Speakers’ Bureau or Honoraria: Regeneron, Sanofi, Lilly, Incyte, Dermavant, Arcutis 

Benjamin Lockshin, MD

Grant/Research Support: Abbvie, Eli Lilly, Celgene, Regeneron, Sanofi Genzyme, DermTech, Exact Sciences, Pfizer, Leo, Arcutis, Dermavant 

Consultant: AbbVie, Eli Lilly, Regeneron, Sanofi Genzyme, DermTech, Exact Sciences, Dermavant, Arcutis, Leo 

Speakers’ Bureau or Honoraria: Abbvie, Eli Lilly, Regeneron, Sanofi Genzyme, Dermavant, Arcutis, Leo

The planners have disclosed that they have no relevant financial relationships with any Ineligible Company in the past 24 months.  

The University of Nevada discloses that all relevant conflicts have been satisfactorily mitigated.


The leading platform for dermatology professionals to elevate patient care.

Contact Us


Subscribe now

Enter your email to get the latest updates.

© 2023 dermsquared | All Rights Reserved